Globalpharma and Ethypharm sign cetirizine deal

2 April 2006

United Arab Emirates-based Globalpharma says it has signed an out-licensing and supply contract with France's Ethypharm for the marketing and distribution of cetirizine antihistamine tablets through the latter's wholly-owned Indian subsidiary, Ethypharm LL.

Under the terms of the deal, Ethypharm will take responsibility for development of the drug using its specialist T-mask technology. Globalpharma will retain responsibility for marketing the product in the Gulf Cooperation Council markets. Financial terms of the deal were not disclosed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight